Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Reliable Are Official Annual Suicide Numbers in Sri Lanka?

Crisis·2026
Same author

Reducing the impact of diabetic foot ulcers (REDUCE): study protocol for an effectiveness and cost-effectiveness randomised controlled trial with embedded process evaluation.

BMJ open·2026
Same author

H3K27M-altered diffuse midline glioma: Experience and outcomes from a low-middle income country setting in the contemporary era.

Neuro-oncology advances·2026
Same author

Suicide prevention: careful and responsible reporting of research.

The British journal of psychiatry : the journal of mental science·2026
Same author

Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care: A Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

The Impact of Hepatitis C and Socio-Demographic Variables on Health-Related Quality of Life in Pakistan: Cross-Sectional Study.

Journal of viral hepatitis·2026

Related Experiment Video

Updated: Jul 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.

Jenny L Donovan1, Freddie C Hamdy2, J Athene Lane1,3

  • 1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

NEJM Evidence
|February 6, 2024
PubMed
Summary
This summary is machine-generated.

Long-term outcomes for localized prostate cancer treatments show similar quality of life but varying functional impacts. Prostatectomy and radiotherapy led to more urinary issues and lower sexual function compared to active monitoring over 7-12 years.

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.7K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.1K

Related Experiment Videos

Last Updated: Jul 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.7K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.1K

Area of Science:

  • Urology
  • Oncology
  • Patient-reported outcomes research

Background:

  • Localized prostate cancer treatment decisions require long-term patient-reported outcome data.
  • The Prostate Testing for Cancer and Treatment (ProtecT) trial evaluated quality of life and functional impacts of different treatment strategies.

Purpose of the Study:

  • To assess long-term (7-12 years) patient-reported functional and quality-of-life outcomes for localized prostate cancer.
  • To compare prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring.

Main Methods:

  • Analysis of patient-reported outcomes from 1643 randomly assigned participants in the ProtecT trial.
  • Focus on data from 7 to 12 years post-randomization.
  • Utilized mixed-effects linear and logistic models to analyze outcomes.

Main Results:

  • Generic quality-of-life scores were similar across treatment groups (prostatectomy, radiotherapy, active monitoring) from 7-12 years.
  • Prostatectomy group reported higher rates of urinary leakage (18-24%) compared to active monitoring (9-11%) and radiotherapy (3-8%).
  • Erectile function sufficient for intercourse declined over time, with lower rates in the prostatectomy group (18% at 7 years) versus active monitoring (30%) and radiotherapy (27%), converging to low levels by year 12.
  • Nocturia rates at 12 years were 34% (prostatectomy), 48% (radiotherapy), and 47% (active monitoring).
  • Fecal leakage affected 12% in the radiotherapy group versus 6% in others by year 12.
  • Active monitoring showed gradual age-related functional declines without radical treatment effects.

Conclusions:

  • The ProtecT trial provides robust, long-term evidence on the continued impacts of localized prostate cancer treatments.
  • Data support informed decision-making by allowing patients and clinicians to weigh treatment benefits against harms.
  • Findings enable more prudent treatment choices for newly diagnosed localized prostate cancer.